EQS-News: Sartorius completes acquisition of MatTek
Werte in diesem Artikel
EQS-News: SARTORIUS AG
/ Key word(s): Mergers & Acquisitions
Werbung Werbung Göttingen, Germany | July 1, 2025
Sartorius completes acquisition of MatTek The life science group Sartorius has successfully closed the acquisition of MatTek Corp, including Visikol Inc, from the Swedish BICO Group AB, as announced in April. The acquisition was completed on July 1, 2025, following the receipt of the required regulatory approval and the fulfillment of other customary closing conditions. With the integration of the business into its Lab Products and Services division, Sartorius is expanding its cell technology portfolio and creating synergies with existing solutions for drug development, including cell analysis instruments, reagents, and AI models. MatTek is a leading developer and manufacturer of human cell-based microtissues and 3D models that accelerate drug development. The advanced cell models mimic the structure and function of human tissue and deliver more accurate, cost-effective, and reproducible results compared to traditional 2D cell cultures, while reducing the need for animal testing. The company employs more than 80 people at its headquarters in Ashland, Massachusetts, USA, and at its production site in Bratislava, Slovakia. A profile of Sartorius Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. Around 13,500 employees are working for customers around the globe. Visit our Newsroom and follow Sartorius on LinkedIn. Contact Leona Malorny Head of External Communications +49 551 308 4067 leona.malorny@sartorius.com Additional features: File: Sartorius completes acquisition of MatTek | Media Release
01.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | SARTORIUS AG |
Otto-Brenner-Straße 20 | |
37079 Göttingen | |
Germany | |
Phone: | +49.(0)551-308.0 |
Fax: | +49.(0)551-308.3289 |
E-mail: | info@sartorius.com |
Internet: | www.sartorius.com |
ISIN: | DE0007165631, DE0007165607 |
WKN: | 716563, 716560 |
Indices: | DAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2162694 |
End of News | EQS News Service |
|
2162694 01.07.2025 CET/CEST
Ausgewählte Hebelprodukte auf Sartorius vz.
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sartorius vz.
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Sartorius AG Vz.
Analysen zu Sartorius AG Vz.
Datum | Rating | Analyst | |
---|---|---|---|
24.06.2025 | Sartorius vz Overweight | JP Morgan Chase & Co. | |
18.06.2025 | Sartorius vz Overweight | Barclays Capital | |
13.06.2025 | Sartorius vz Hold | Jefferies & Company Inc. | |
06.06.2025 | Sartorius vz Neutral | UBS AG | |
21.05.2025 | Sartorius vz Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
24.06.2025 | Sartorius vz Overweight | JP Morgan Chase & Co. | |
18.06.2025 | Sartorius vz Overweight | Barclays Capital | |
25.04.2025 | Sartorius vz Overweight | JP Morgan Chase & Co. | |
17.04.2025 | Sartorius vz Buy | Deutsche Bank AG | |
26.03.2025 | Sartorius vz Overweight | JP Morgan Chase & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
13.06.2025 | Sartorius vz Hold | Jefferies & Company Inc. | |
06.06.2025 | Sartorius vz Neutral | UBS AG | |
21.05.2025 | Sartorius vz Sector Perform | RBC Capital Markets | |
12.05.2025 | Sartorius vz Hold | Jefferies & Company Inc. | |
23.04.2025 | Sartorius vz Hold | Jefferies & Company Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
29.01.2025 | Sartorius vz Verkaufen | DZ BANK | |
28.01.2025 | Sartorius vz Underperform | Bernstein Research | |
15.01.2025 | Sartorius vz Underperform | Bernstein Research | |
06.01.2025 | Sartorius vz Underperform | Bernstein Research | |
06.01.2025 | Sartorius vz Underperform | Bernstein Research |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sartorius AG Vz. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen